| Title | Authors (identified) | Published In | Identifier(s) | Topic | Published Date | Match? |
|---|
| Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry) | [1]Sara López-Tarruella, [2]M J Escudero, [3]Marina Pollan, [4]Miguel Martin, [5]Carlos Jara, [6]Begoña Bermejo, [7]Angel Guerrero-Zotano, [8]José García-Saenz, [9]Ana Santaballa, [10]Emilio Alba, [11]Raquel Andrés, [12]Purificación Martínez, [13]Lourdes Calvo, [14]Antonio Fernández-Aramburo, [15]Norberto Batista, ... [Full author list] | Scientific Reports [missing] | DOI: 10.1038/S41598-019-55765-9 [ORCID]
PubMed: 31882586 [ORCID]
| metastatic breast cancer [missing] | 2019-12-27 | |
| Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) | [1]Ana Lluch, [2]Carlos H Barrios, [3]Laura Torrecillas, [4]Manuel Ruiz-Borrego, [5]Jose Bines, [6]Jose Segalla, [7]Ángel Guerrero-Zotano, [8]Jose A García-Sáenz, [9]Roberto Torres, [10]Juan de la Haba, ..., [15]José M Baena-Cañada, [16]Agustí Barnadas, [17]Lourdes Calvo, [18]Laura Pérez-Michel, [19]Manuel Ramos, ... [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.19.00904 [ORCID]
PubMed: 31804894 [ORCID]
| capecitabine [missing]; triple-negative breast cancer [missing]; phase III clinical trial [missing] | 2019-12-05 | |
| Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q" | [1]Rosario González Mancha, [2]Montserrat Muñoz, [3]Luis de la Cruz-Merino, [4]Lourdes Calvo, [5]Josefina Cruz, [6]Jose Manuel Baena-Cañada, [7]Yolanda Fernandez, [8]Manuel Ramos, [9]Cesar Augusto Rodriguez, [10]Jose Ignacio Chacón, [11]Isabel Palomero, [12]Julia Llinares, [13]María Rivero, [14]Miguel Ruiz [Full author list] | Health and Quality of Life Outcomes [missing] | DOI: 10.1186/S12955-019-1197-7 [ORCID]
PubMed: 31420041 [ORCID]
| | 2019-08-17 | |
| Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists | [1]Pedro Sánchez-Rovira, [2]Pilar Zamora, [3]Javier Salvador-Bofill, [4]Serafín Morales, [5]Noelia Martínez-Jáñez, [6]Eduardo Martínez-de-Dueñas, [7]Ana Lluch, [8]José Juan Illarramendi, [9]Patricia Gómez-Pardo, [10]Joaquín Gavilá Gregori, [11]Andrés García-Palomo, [12]Jesús García-Mata, [13]Yolanda Fernández, [14]Sonia Del Barco, [15]Ana de Juan, [16]Eva Ciruelos, [17]José Ignacio Chacón, [18]Lourdes Calvo, [19]Agustí Barnadas, [20]Joan Albanell [Full author list] | Journal of drug assessment [missing] | DOI: 10.1080/21556660.2019.1604375 [ORCID]
PubMed: 31069129 [ORCID]
| hormone therapy [missing]; metastatic breast cancer [missing]; Clinical Practice [missing] | 2019-01-01 | |
| Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study | [1]Vanesa Ortega, [2]Antonio Antón, [3]Isabel Garau, [4]Noemia Afonso, [5]Lourdes Calvo, [6]Yolanda Fernández, [7]María Martínez-García, [8]Esperanza Blanco, [9]Pilar Zamora, [10]Mirta García, [11]José Juan Illarramendi, [12]César Augusto Rodríguez Sánchez, [13]Miguel Sampayo, [14]Elena Aguirre, [15]José Manuel Pérez-García, [16]Javier Cortés, [17]Antonio Llombart-Cussac [Full author list] | Clinical Breast Cancer [missing] | DOI: 10.1016/J.CLBC.2018.12.012 [ORCID]
PubMed: 30679100 [ORCID]
| multicenter clinical trial [missing]; metastatic breast cancer [missing]; phase II clinical trial [missing] | 2018-12-20 | |
| Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-the Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. | [1]Luca Gianni, [2]Mauro Mansutti, [3]Antonio Anton, [4]Lourdes Calvo, [5]Giancarlo Bisagni, [6]Begoña Bermejo, [7]Vladimir Semiglazov, [8]Marc Thill, [9]Jose Ignacio Chacon, [10]Arlene Chan, ... [Full author list] | JAMA Oncology [missing] | DOI: 10.1001/JAMAONCOL.2017.4612 [ORCID]
PubMed: 29327055 [ORCID]
| paclitaxel [missing]; phase III clinical trial [missing] | 2018-01-11 | |
| Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study | [1]Ivan Marquez-Rodas, [2]Marina Pollan, [3]María José Escudero, [4]Amparo Ruiz, [5]Miguel Martín, [6]Ana Santaballa, [7]Purificación Martínez Del Prado, [8]Norberto Batista, [9]Raquel Andrés, [10]Antonio Antón, ..., [14]Sonia González, [15]Miguel Angel Seguí, [16]Lourdes Calvo, [17]José Lizón, [18]Álvaro Rodríguez Lescure, ... [Full author list] | PLOS One [missing] | DOI: 10.1371/JOURNAL.PONE.0184181 [ORCID]
PubMed: 28985233 [ORCID]
| | 2017-10-06 | |
| Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis | [1]Miguel Martín, [2]José I Chacón, [3]Antonio Antón, [4]Arrate Plazaola, [5]Elena García-Martínez, [6]Miguel A Seguí, [7]Pedro Sánchez-Rovira, [8]José Palacios, [9]Lourdes Calvo, [10]Carmen Esteban, [11]Enrique Espinosa, ... [Full author list] | Oncologist [missing] | DOI: 10.1634/THEONCOLOGIST.2017-0052 [ORCID]
PubMed: 28701571 [ORCID]
| nanoparticle [missing]; paclitaxel [missing]; biomarker [missing]; multicenter clinical trial [missing]; phase II clinical trial [missing] | 2017-07-12 | |
| Physical activity and breast cancer risk by pathological subtype | [1]Virginia Lope, [2]Miguel Martín, [3]Adela Castelló, [4]Soraya Casla, [5]Amparo Ruiz, [6]Jose Manuel Baena-Cañada, [7]Ana Mª Casas, [8]Lourdes Calvo, [9]Begoña Bermejo, [10]Montserrat Muñoz, ... [Full author list] | Gynecologic Oncology [missing] | DOI: 10.1016/J.YGYNO.2016.12.014 [ORCID]
PubMed: 28057355 [ORCID]
| | 2017-01-02 | |
| A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse | [1]Aleix Prat, [2]Ana Lluch, [3]Arran K Turnbull, [4]Anita Dunbier, [5]Lourdes Calvo, [6]Joan Albanell, [7]Juan de la Haba-Rodríguez, [8]Angels Arcusa, [9]José Ignacio Chacón, [10]Pedro Sánchez-Rovira, ... [Full author list] | Clinical Cancer Research [missing] | DOI: 10.1158/1078-0432.CCR-16-2092 [ORCID]
PubMed: 27903675 [ORCID]
| | 2016-11-30 | |
| High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. | [1]Emilio Alba, [2]Ana Lluch, [3]Nuria Ribelles, [4]Antonio Anton-Torres, [5]Pedro Sanchez-Rovira, [6]Joan Albanell, [7]Lourdes Calvo, [8]Jose Antonio Lopez García-Asenjo, [9]Jose Palacios, [10]Jose Ignacio Chacon, ... [Full author list] | Oncologist [missing] | DOI: 10.1634/THEONCOLOGIST.2015-0312ERRATUM [ORCID]
PubMed: 27317735 [ORCID]
| | 2016-06-01 | |
| Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study | [1]Antonio Llombart-Cussac, [2]Manuel Ramos, [3]Elsa Dalmau, [4]Jose A Garcia-Saenz, [5]Xavier Gonzàlez Farré, [6]Laura Murillo, [7]Lourdes Calvo, [8]Serafin Morales, [9]Vicente Carañana, [10]Ana González, [11]Luís Fernández-Morales, [12]Fernando Moreno, [13]M Isabel Casas, [14]M Del Mar Angulo, [15]M Carmen Cámara, [16]Ana I Garcia-Mace, [17]Eva Carrasco, [18]Carlos Jara-Sánchez [Full author list] | European Journal of Cancer [missing] | DOI: 10.1016/J.EJCA.2016.01.015 [ORCID]
PubMed: 26994459 [ORCID]
| docetaxel [missing] | 2016-03-16 | |
| Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study | [1]Miguel Martin, [2]Jan C Brase, [3]Amparo Ruiz, [4]Aleix Prat, [5]Ralf Kronenwett, [6]Lourdes Calvo, [7]Christoph Petry, [8]Philip S Bernard, [9]Manuel Ruiz-Borrego, [10]Karsten E Weber, [11]César A Rodriguez, [12]Isabel Alvarez, [13]Miguel A Segui, [14]Charles M. Perou, [15]Maribel Casas, [16]Eva Carrasco, [17]Rosalía Caballero, [18]Alvaro Rodriguez-Lescure [Full author list] | Breast Cancer Research and Treatment [missing] | DOI: 10.1007/S10549-016-3725-Z [ORCID]
PubMed: 26909792 [ORCID]
| | 2016-02-24 | |
| High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer | [1]Emilio Alba, [2]Ana Lluch, [3]Nuria Ribelles, [4]Antonio Anton-Torres, [5]Pedro Sanchez-Rovira, [6]Joan Albanell, [7]Lourdes Calvo, [8]Jose Antonio Lopez García-Asenjo, [9]Jose Palacios, [10]Jose Ignacio Chacon, ... [Full author list] | Oncologist [missing] | DOI: 10.1634/THEONCOLOGIST.2015-0312 [ORCID]
PubMed: 26786263 [ORCID]
| chemotherapy [missing] | 2016-01-19 | |
| Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile | [1]Antonio González-Martín, [10]Francisco Ayala de la Peña, [11]Agustí Barnadas, [12]Norberto Batista, [13]Lourdes Calvo, [14]Elena Galve, [15]Andrés García-Palomo, ..., [2]Emilio Alba, [3]Eva M Ciruelos, [4]Javier Cortes, [5]Antonio Llombart, [6]Ana Lluch, [7]Raquel Andrés, [8]Isabel Alvarez, [9]José Manuel Aramendía, ... [Full author list] | Current Cancer Drug Targets [missing] | DOI: 10.2174/1568009615666150817121731 [ORCID]
PubMed: 26278712 [ORCID]
| metastatic breast cancer [missing] | 2016-01-01 | |
| Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study | [1]Miguel Martín, [2]Amparo Ruiz Simón, [3]Manuel Ruiz Borrego, [4]Nuria Ribelles, [5]Álvaro Rodríguez-Lescure, [6]Montserrat Muñoz-Mateu, [7]Sonia González, [8]Mireia Margelí Vila, [9]Agustí Barnadas, [10]Manuel Ramos, [11]Sonia Del Barco Berron, [12]Carlos Jara, [13]Lourdes Calvo, [14]Noelia Martínez-Jáñez, [15]César Mendiola Fernández, ... [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.2015.61.9510 [ORCID]
PubMed: 26416999 [ORCID]
| capecitabine [missing]; docetaxel [missing] | 2015-09-28 | |
| Defining breast cancer intrinsic subtypes by quantitative receptor expression | [1]Maggie Chon U Cheang, [2]Miguel Martin, [3]Torsten O Nielsen, [4]Aleix Prat, [5]David Voduc, [6]Alvaro Rodriguez-Lescure, [7]Amparo Ruiz, [8]Stephen Chia, [9]Lois Shepherd, [10]Manuel Ruiz-Borrego, [11]Lourdes Calvo, [12]E Alba, [13]Eva Carrasco, ... [Full author list] | Oncologist [missing] | DOI: 10.1634/THEONCOLOGIST.2014-0372 [ORCID]
PubMed: 25908555 [ORCID]
| | 2015-04-23 | |
| Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis | [1]Miguel Martin, [2]Noelia Martínez, [3]Manuel Ramos, [4]Lourdes Calvo, [5]Ana Lluch, [6]Pilar Zamora, [7]Montserrat Muñoz, [8]Eva Carrasco, [9]Rosalía Caballero, [10]Jose A Garcia-Saenz, ... [Full author list] | Oncologist [missing] | DOI: 10.1634/THEONCOLOGIST.2014-0379 [ORCID]
PubMed: 25601966 [ORCID]
| capecitabine [missing]; metastatic breast cancer [missing]; phase II clinical trial [missing] | 2015-01-19 | |
| Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study) | [1]Agustí Barnadas, [2]Luis Manso, [3]Concepción de la Piedra, [4]Cristina Meseguer, [5]Carmen Crespo, [6]Patricia Gómez, [7]Lourdes Calvo, [8]Purificación Martinez, [9]Manuel Ruiz-Borrego, [10]Antonia Perelló, ... [Full author list] | Bone [missing] | DOI: 10.1016/J.BONE.2014.07.036 [ORCID]
PubMed: 25108081 [ORCID]
| | 2014-08-07 | |
| Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial | [1]Miguel Martin, [2]Jan C Brase, [3]Lourdes Calvo, [4]Kristin Krappmann, [5]Manuel Ruiz-Borrego, [6]Karin Fisch, [7]Amparo Ruiz, [8]Karsten E Weber, [9]Blanca Munarriz, [10]Christoph Petry, [11]Cesar A Rodriguez, [12]Ralf Kronenwett, [13]Carmen Crespo, [14]Emilio Alba, [15]Eva Carrasco, [16]Maribel Casas, [17]Rosalía Caballero, [18]Alvaro Rodriguez-Lescure [Full author list] | Breast Cancer Research [missing] | DOI: 10.1186/BCR3642 [ORCID]
PubMed: 24725534 [ORCID]
| chemotherapy [missing] | 2014-04-12 | |
| Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis | [1]Bella Pajares, [2]Marina Pollan, [3]Miguel Martin, [4]John R. Mackey, [5]Ana Lluch, [6]Joaquín Gavila, [7]Charles Vogel, [8]Manuel Ruiz-Borrego, [9]Lourdes Calvo, [10]Tadeusz Pieńkowski, [11]Álvaro Rodríguez-Lescure, [12]Miguel Angel Seguí, [13]Olivier Trédan, [14]Antonio Antón, [15]Manuel Ramos, [16]María del Carmen Cámara, [17]César Rodríguez-Martín, [18]Eva Carrasco, [19]E Alba [Full author list] | Breast Cancer Research [missing] | DOI: 10.1186/BCR3572 [ORCID]
PubMed: 24192331 [ORCID]
| obesity [missing] | 2013-11-06 | |
| Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study | [1]Miguel Martin, [2]Amparo Ruiz, [3]Manuel Ruiz Borrego, [4]Agustí Barnadas, [5]Sonia González, [6]Lourdes Calvo, [7]Mireia Margelí Vila, [8]Antonio Antón, [9]Alvaro Rodríguez-Lescure, [10]Miguel Angel Seguí-Palmer, ... [Full author list] | Journal of Clinical Oncology [missing] | DOI: 10.1200/JCO.2012.46.9841 [ORCID]
PubMed: 23733779 [ORCID]
| doxorubicin [missing]; fluorouracil [missing]; paclitaxel [missing] | 2013-06-03 | |
| A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study | [1]Silvia Antolín, [2]Ramón Mel, [3]Manuel Ramos, [4]Andrés García-Palomo, [5]Concepción Almanza, [6]Laura de Paz, [7]Lourdes Calvo, [8]Elena Alvarez, [9]Ana González, [10]Jesús García-Mata [Full author list] | Clinical and Translational Oncology [missing] | DOI: 10.1007/S12094-011-0715-9 [ORCID]
PubMed: 21865141 [ORCID]
| doxorubicin [missing]; docetaxel [missing] | 2011-09-01 | |
| Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer | [1]Antonio Guerrero, [2]Sonia Servitja, [3]Alvaro Rodríguez-Lescure, [4]Lourdes Calvo, [5]Sonia del Barco, [6]María Teresa Quintanar, [7]José Ignacio Juárez, [8]Javier Gayo, [9]Antonio Llombart, [10]Ignasi Tusquets [Full author list] | Anti-Cancer Drugs [missing] | DOI: 10.1097/CAD.0B013E3283425C55 [ORCID]
PubMed: 21150776 [ORCID]
| oxaliplatin [missing]; metastatic breast cancer [missing] | 2011-03-01 | |
| Adjuvant docetaxel for high-risk, node-negative breast cancer | [1]Miguel Martín, [2]Miguel A Seguí, [3]Antonio Antón, [4]Amparo Ruiz, [5]Manuel Ramos, [6]Encarna Adrover, [7]Ignacio Aranda, [8]Alvaro Rodríguez-Lescure, [9]Regina Grosse, [10]Lourdes Calvo, [11]Agustí Barnadas, [12]Dolores Isla, ... [Full author list] | The New England Journal of Medicine [missing] | DOI: 10.1056/NEJMOA0910320 [ORCID]
PubMed: 21121833 [ORCID]
| docetaxel [missing] | 2010-12-01 | |
| Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer | [1]Juan de la Haba-Rodríguez, [2]Alvaro Rodríguez-Lescure, [3]Amparo Ruiz, [4]Emilio Alba, [5]Lourdes Calvo, [6]Eva Carrasco, [7]Maria Jose Escudero, [8]Miguel Martin [Full author list] | Breast Cancer Research and Treatment [missing] | DOI: 10.1007/S10549-010-1136-0 [ORCID]
PubMed: 20803065 [ORCID]
| | 2010-08-28 | |
| Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer | [1]Miguel Martín, [2]Alvaro Rodríguez-Lescure, [3]Amparo Ruiz, [4]Emilio Alba, [5]Lourdes Calvo, [6]Manuel Ruiz-Borrego, [7]Ana Santaballa, [8]César A Rodríguez, [9]Carmen Crespo, [10]Mar Abad, ... [Full author list] | Breast Cancer Research and Treatment [missing] | DOI: 10.1007/S10549-009-0663-Z [ORCID]
PubMed: 20037779 [ORCID]
| paclitaxel [missing] | 2010-08-01 | |
| Novel therapeutic approaches to the treatment of metastatic breast cancer | [1]Yolanda Fernández, [2]Juan Cueva, [3]Andrés G Palomo, [4]Manuel Ramos, [5]Ana de Juan, [6]Lourdes Calvo, [7]Jesús García-Mata, [8]Paula García-Teijido, [9]Ignacio Peláez, [10]Laura García-Estévez [Full author list] | Cancer Treatment Reviews [missing] | DOI: 10.1016/J.CTRV.2009.10.001 [ORCID]
PubMed: 19883980 [ORCID]
| metastatic breast cancer [missing] | 2009-11-01 | |
| Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer | [1]Jesus García-Mata, [2]Andres García-Palomo, [3]Lourdes Calvo, [4]Ramon Mel, [5]Juan Jesus Cruz, [6]Manuel Ramos [Full author list] | Clinical and Translational Oncology [missing] | DOI: 10.1007/S12094-008-0280-Z [ORCID]
PubMed: 19015070 [ORCID]
| doxorubicin [missing]; docetaxel [missing] | 2008-11-01 | |
| Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer | [1]Miguel Martín, [2]Alvaro Rodríguez-Lescure, [3]Amparo Ruiz, [4]Emilio Alba, [5]Lourdes Calvo, [6]Manuel Ruiz-Borrego, [7]Blanca Munárriz, [8]César A Rodríguez, [9]Carmen Crespo, [10]Enrique de Alava, ... [Full author list] | Journal of the National Cancer Institute [missing] | DOI: 10.1093/JNCI/DJN151 [ORCID]
PubMed: 18505968 [ORCID]
| fluorouracil [missing]; paclitaxel [missing]; phase III clinical trial [missing] | 2008-05-27 | |
| Neoadjuvant endocrine therapy for breast cancer: past, present and future | [1]Agustí Barnadas, [2]Miguel Gil, [3]Pedro Sánchez-Rovira, [4]Antonio Llombart, [5]Encarna Adrover, [6]Laura G Estevez, [7]Juan de la Haba, [8]Lourdes Calvo [Full author list] | Anti-Cancer Drugs [missing] | DOI: 10.1097/CAD.0B013E3282F97F75 [ORCID]
PubMed: 18454044 [ORCID]
| | 2008-04-01 | |
| A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma | [1]Ramon Colomer, [2]Mariano Monzo, [3]Ignasi Tusquets, [4]Juli Rifa, [5]José M Baena, [6]Agusti Barnadas, [7]Lourdes Calvo, [8]Francisco Carabantes, [9]Carmen Crespo, [10]Montserrat Muñoz, [11]Antonio Llombart, [12]Arrate Plazaola, [13]Rosa Artells, [14]Monstsrrat Gilabert, [15]Belen Lloveras, [16]Emilio Alba [Full author list] | Clinical Cancer Research [missing] | DOI: 10.1158/1078-0432.CCR-07-1923 [ORCID]
PubMed: 18245543 [ORCID]
| single-nucleotide polymorphism [missing] | 2008-02-01 | |
| Time-to-progression in breast cancer: a stratification model for clinical trials | [1]Juan de la Haba-Rodríguez, [2]Enrique Aranda, [3]Antonio Llombart, [4]Ana Lluch, [5]Emilio Alba, [6]Blanca Munárriz, [7]Encarna Adrover, [8]Ignacio Tusquets, [9]Ana Balil, [10]Agustí Barnadas, [11]Lourdes Calvo, [12]Miguel Martin, [13]Grupo Español de Investigación en Cáncer de Mama (GEICAM) [Full author list] | The Breast [missing] | DOI: 10.1016/J.BREAST.2007.09.007 [ORCID]
PubMed: 18042386 [ORCID]
| | 2007-11-26 | |
| Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial | [1]Miguel Martin, [2]Amparo Ruiz, [3]Monserrat Muñoz, [4]Ana Balil, [5]Jesús García-Mata, [6]Lourdes Calvo, [7]Eva Carrasco, [8]Esther Mahillo, [9]Antonio Casado, [10]Jose A Garcia-Saenz, ... [Full author list] | Lancet Oncology Commission [missing] | DOI: 10.1016/S1470-2045(07)70041-4 [ORCID]
PubMed: 17329192 [ORCID]
| metastatic breast cancer [missing]; phase III clinical trial [missing] | 2007-03-01 | |
| Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial | [1]Amadeu Pelegrí, [2]Lourdes Calvo, [3]Antonio Antón, [4]José I Mayordomo, [5]Jesus Florián, [6]Santiago Vásquez, [7]Angels Arcusa, [8]Marta Martín-Richard, [9]José L Bayo, [10]Eva Carrasco, [11]Javier Virizuela, [12]Spanish Group for Breast Cancer Research (GEICAM) [Full author list] | Clinical Breast Cancer [missing] | DOI: 10.3816/CBC.2005.N.048 [ORCID]
PubMed: 16381627 [ORCID]
| metastatic breast cancer [missing]; phase II clinical trial [missing] | 2005-12-01 | |
| Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial | [1]Amadeu Pelegrí, [2]Lourdes Calvo, [3]José I Mayordomo, [4]Jesús Florián, [5]Santiago Vázquez, [6]Angels Arcusa, [7]Marta Martn-Richard, [8]José L Bayo, [9]Javier Virizuela, [10]Eva Carrasco, [11]Antonio Antón, [12]Spanish Group for Breast Cancer Research (GEICAM) [Full author list] | Seminars in Oncology [missing] | DOI: 10.1053/J.SEMINONCOL.2004.03.023 [ORCID]
PubMed: 15199528 [ORCID]
| docetaxel [missing]; metastatic breast cancer [missing]; phase II clinical trial [missing] | 2004-04-01 | |